NASDAQ:ABUS Arbutus Biopharma Q3 2026 Earnings Results & Report $3.78 +0.07 (+1.75%) As of 03:12 PM Eastern This is a fair market value price provided by Massive. Learn more. Arbutus Biopharma beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released November 10, 2026. The company reported EPS of $0.30 versus the -$0.0232 consensus estimate, while revenue of $299 thousand fell short of the $1 million estimate by $701.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call7:00 AM ET Arbutus Biopharma EPS ResultsActual EPS$0.30Consensus EPS -$0.0232Beat/MissBeat by +$0.3232One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersArbutus Biopharma Revenue ResultsActual Revenue$299 thousandExpected Revenue$1 millionBeat/MissMissed by -$701.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Arbutus Biopharma Q3 2026 Earnings FAQ Did Arbutus Biopharma beat earnings estimates for Q3 2026? Arbutus Biopharma (NASDAQ:ABUS) reported earnings of $0.30 per share for Q3 2026, beating the consensus estimate of -$0.0232. The report was announced on Tuesday, November 10, 2026. What was Arbutus Biopharma's revenue for Q3 2026? Arbutus Biopharma reported revenue of $299 thousand for Q3 2026, against a consensus estimate of $1 million. Arbutus Biopharma Earnings HeadlinesArbutus Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 10 at 7:30 AM | globenewswire.comArbutus Biopharma's AB-101 Gets FDA Hold Lifted In Hepatitis B ProgramOctober 22, 2026 | rttnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 10 at 1:00 AM | Behind the Markets (Ad)Arbutus Says US Lifts Clinical Hold on AB-101 Hepatitis B DrugOctober 22, 2026 | finance.yahoo.comArbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 InhibitorOctober 22, 2026 | globenewswire.comArbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV CureOctober 8, 2026 | seekingalpha.comSee More Arbutus Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email. Email Address About Arbutus BiopharmaArbutus Biopharma (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company focused on developing treatments for chronic hepatitis B virus (HBV) infection. Its research programs include RNA interference (RNAi) therapies, immune-based treatments and capsid assembly inhibitors, which target different aspects of the virus and the body’s response to infection. The company’s investigational portfolio includes imdusiran, an RNAi therapeutic designed to reduce hepatitis B surface antigen, as well as other HBV drug candidates at various stages of development. Arbutus also develops drug-delivery technologies, including lipid nanoparticles and GalNAc-based approaches. Arbutus adopted its current name in 2015 following the merger of Tekmira Pharmaceuticals and OnCore Biopharma. The company’s research and development efforts remain centered on advancing potential therapies for people with chronic HBV infection.View Arbutus Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
